RANI Stock Price, Rani Therapeutics Holdings, . Quote, Chart

Market Summary

USD6.99+0.30

Market Closed

4.48%

RANI Stock Price

View Fullscreen

RANI RSI Chart

RANI Valuation

Market Cap

174.4M

Price/Earnings (Trailing)

-4.07

Price/Sales (Trailing)

52.82

EV/EBITDA

-3.16

Price/Free Cashflow

-3.33

RANI Price/Sales (Trailing)

RANI Profitability

EBT Margin

-2056.44%

Return on Equity

-333.29%

Return on Assets

-74.04%

Free Cashflow Yield

-30.07%

RANI Fundamentals

RANI Revenue

Revenue (TTM)

3.3M

Rev. Growth (Yr)

-17.48%

Rev. Growth (Qtr)

-19.55%

RANI Earnings

Earnings (TTM)

-42.9M

Earnings Growth (Yr)

323.08%

Earnings Growth (Qtr)

119.71%

Breaking Down RANI Revenue

Last 7 days

-11.0%

Last 30 days

116.4%

Last 90 days

91.0%

Trailing 12 Months

52.3%

How does RANI drawdown profile look like?

RANI Financial Health

Current Ratio

6.36

Debt/Equity

1.9

Debt/Cashflow

-2.09

RANI Investor Care

Shares Dilution (1Y)

4.43%

Diluted EPS (TTM)

-1.33

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	2.1M	3.0M	3.4M	3.3M
2022	2.3M	2.0M	1.6M	1.2M
2021	1.0M	1.6M	2.2M	2.7M
2020	0	0	0	462.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Rani Therapeutics Holdings, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 06, 2023	imran talat	bought	22,700	2.27	10,000	chief executive officer
Dec 04, 2023	imran talat	bought	12,850	2.57	5,000	chief executive officer
Nov 29, 2023	imran talat	bought	41,000	2.05	20,000	chief executive officer
Nov 24, 2023	south cone investments limited partnership	bought	10,583,000	2.01	5,265,160	-
Nov 24, 2023	quiroga cortes isidoro alfonso	sold	-10,583,000	2.01	-5,265,160	-
Nov 17, 2023	butel jean luc	bought	102,495	2.0296	50,500	-
Nov 16, 2023	nanavaty maulik	bought	990	1.98	500	-
Nov 07, 2023	imran talat	bought	9,975	1.995	5,000	chief executive officer
May 12, 2023	south cone investments limited partnership	bought	10,529	3.9809	2,645	-
May 11, 2023	south cone investments limited partnership	bought	10,096	3.8683	2,610	-

Which funds bought or sold RANI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	added	22.92	14,135	30,265	-%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-0.11	763,643	2,218,910	-%
Feb 14, 2024	Royal Bank of Canada	reduced	-72.09	-	-	-%
Feb 14, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	58,967	170,980	-%
Feb 14, 2024	LASRY MARC	unchanged	-	72,006	208,785	0.31%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-100,348	-	-%
Feb 14, 2024	Alpha Square Group S LLC	reduced	-32.2	6,593	195,701	0.23%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	reduced	-44.83	-71,148	379,340	-%
Feb 14, 2024	STATE STREET CORP	unchanged	-	38,634	112,023	-%

Are Funds Buying or Selling RANI?

Are funds buying RANI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RANI

No. of Funds

Unveiling Rani Therapeutics Holdings, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Dec 08, 2023	south lake one llc	46.9%	12,131,554	SC 13D/A
Dec 08, 2023	quiroga cortes isidoro alfonso	0%	8,400	SC 13D/A
Mar 15, 2023	south lake one llc	27.20%	6,778,550	SC 13D/A
Feb 14, 2022	incube ventures ii, l.p.	11.5%	2,566,113	SC 13G

Recent SEC filings of Rani Therapeutics Holdings, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 17, 2024	DEFA14A	DEFA14A
Apr 17, 2024	DEF 14A	DEF 14A
Apr 17, 2024	ARS	ARS
Mar 22, 2024	4	Insider Trading
Mar 22, 2024	4	Insider Trading
Mar 22, 2024	4	Insider Trading
Mar 22, 2024	4	Insider Trading
Mar 22, 2024	4	Insider Trading
Mar 20, 2024	S-8	Employee Benefits Plan
Mar 20, 2024	8-K	Current Report

Peers (Alternatives to Rani Therapeutics Holdings, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	-1.39%	-19.31%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.44%	-28.86%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	5.41%	-4.57%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.99%	-29.65%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-10.10%	-42.90%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-14.83%	70.74%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-7.99%	-0.08%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.49%	-30.64%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-7.01%	-17.50%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.67%	-6.03%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-13.72%	-45.61%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	-0.25%	294.45%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-18.06%	3.25%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	70.91%	57.98%	-0.24	2.14	-13.45%	66.37%

Rani Therapeutics Holdings, Inc. News

Latest updates

Rani Therapeutics Holdings, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Revenue	-19.5%	675,000	839,000	896,000	891,000	818,000	379,000	35,000	17,500	-	-	1,961,000	756,000	432,000	108,000	60,000
Operating Expenses	-24.8%	13,434,000	17,855,000	18,294,000	16,516,000	17,482,000	16,342,000	15,847,000	13,780,000	13,362,000	27,781,000	7,219,000	5,954,000	-	2,935,000	3,450,000
S&GA Expenses	-12.2%	5,828,000	6,635,000	7,208,000	6,804,000	7,096,500	7,239,000	6,319,000	6,189,000	5,945,000	15,822,000	3,460,000	2,607,000	-	845,000	892,000
R&D Expenses	-32.2%	7,606,000	11,220,000	11,086,000	9,712,000	10,385,500	9,103,000	9,528,000	7,591,000	7,417,000	11,959,000	3,759,000	3,347,000	-	2,090,000	2,558,000
EBITDA Margin	1.9%	-18.77	-19.14	-21.77	-29.88	-49.40	-36.15	-35.82	-25.75	-19.17	-7.41	-10.04	-15.55	-34.53	-31.14	-42.57
Interest Expenses	-1.5%	1,296,000	1,316,000	1,266,000	1,207,000	719,000	352,000	-	-	-1,000	110,000	169,000	188,000	-	64,000	2,000
Income Taxes	-	-	-	-	-	-117,500	107,000	154,000	63,000	-40,000	37,000	1,000	43,000	-	5,000	6,000
Earnings Before Taxes	23.3%	-14,055,000	-18,332,000	-18,664,000	-16,832,000	-17,382,500	-16,315,000	-15,812,000	-13,765,000	-13,345,000	-28,663,000	-5,484,000	-5,555,000	-	-2,878,000	-2,708,000
EBT Margin	0.5%	-20.56	-20.68	-23.19	-31.25	-50.70	-36.67	-36.11	-26.07	-19.52	-7.74	-10.49	-16.25	-36.08	-33.25	-45.13
Net Income	119.7%	1,812,500	-9,197,000	-18,664,000	-16,832,000	-812,500	-7,955,000	-15,966,000	-13,828,000	352,500	-3,142,000	-5,485,000	-5,598,000	-5,756,000	-2,883,000	-2,714,000
Net Income Margin	1.7%	-12.99	-13.21	-14.83	-19.58	-30.90	-23.15	-16.44	-9.41	-5.11	-9.28	-12.41	-16.53	-36.15	-43.44	-67.20
Free Cashflow	14.7%	-12,603,000	-14,782,000	-12,636,000	-12,402,000	-15,159,000	-12,654,000	-10,707,000	-9,614,000	-11,720,000	-11,120,000	-5,764,000	-4,147,000	-	670,000	-4,937,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q2	2020Q4
Assets	-17.8%	58.00	70.00	84.00	96.00	108	108	104	115	124	137	77.00	78.00	79.00
Current Assets	-19.6%	51.00	63.00	76.00	89.00	101	101	98.00	109	120	132	69.00	-	75.00
Cash Equivalents	17.9%	6.00	5.00	8.00	19.00	27.00	27.00	97.00	108	117	130	69.00	0.00	73.00
Net PPE	-2.4%	6.00	6.00	6.00	6.00	6.00	6.00	5.00	5.00	5.00	5.00	4.00	-	4.00
Liabilities	-8.8%	32.00	36.00	35.00	35.00	34.00	22.00	6.00	5.00	3.00	5.00	10.00	-	8.00
Current Liabilities	8.8%	8.00	7.00	6.00	5.00	5.00	7.00	5.00	4.00	3.00	5.00	9.00	-	5.00
Long Term Debt	-12.9%	24.00	28.00	29.00	29.00	29.00	14.00	-	-	-	-	-	-	2.00
LT Debt, Current	300.7%	5.00	1.00	-	-	-	-	-	-	-	-	4.00	-	1.00
LT Debt, Non Current	-12.9%	24.00	28.00	29.00	29.00	29.00	14.00	-	-	-	-	-	-	2.00
Shareholder's Equity	-26.7%	13.00	18.00	48.00	62.00	37.00	87.00	99.00	111	122	132	0.00	0.00	-
Retained Earnings	-10.8%	-72.90	-65.80	-56.60	-47.30	-38.92	-30.13	-22.18	-14.60	-8.33	-3.14	-125	-	-114
Additional Paid-In Capital	2.9%	86.00	83.00	81.00	78.00	76.00	72.00	70.00	68.00	56.00	55.00	0.00	0.00	-
Shares Outstanding	-100.0%	-	26.00	25.00	25.00	-	24.00	23.00	21.00	20.00	19.00	47.00	-	-
Minority Interest	-27.2%	13.00	17.00	24.00	31.00	37.00	44.00	51.00	57.00	74.00	80.00	-	-	-
Float	-	-	-	54.00	-	-	-	128	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	13.3%	-12,436	-14,345	-12,255	-12,200	-14,629	-12,198	-10,328	-9,360	-11,449	-11,120	-5,628	-4,048	-	-	-
Share Based Compensation	-9.7%	4,486	4,966	5,141	4,415	4,499	4,402	3,976	2,905	3,164	18,696	282	453	-	-	-
Cashflow From Investing	13.7%	13,274	11,674	789	4,123	-457	-71,346	-379	-254	-271	-	-136	-99.00	-	-	-
Cashflow From Financing	95.9%	96.00	49.00	80.00	8.00	14,874	14,082	49.00	-	-570	71,549	-1,584	7,751	-	-	-

RANI Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses
Research and development	$ 39,624	$ 36,607
General and administrative	26,475	26,844
Total operating expenses	66,099	63,451
Loss from operations	(66,099)	(63,451)
Other income (expense), net
Interest income and other, net	3,301	1,248
Interest expense and other, net	(5,085)	(1,071)
Loss before income taxes	(67,883)	(63,274)
Income tax expense (benefit)	0	(70)
Net loss	(67,883)	(63,344)
Net loss attributable to non-controlling interest	(33,913)	(32,756)
Net loss attributable to Rani Therapeutics Holdings, Inc.	$ (33,970)	$ (30,588)
Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc.-basic	$ (1.33)	$ (1.28)
Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc.-diluted	$ (1.33)	$ (1.28)
Weighted average Class A common share outstanding-basic	25,505	23,817
Weighted average Class A common share outstanding-diluted	25,505	23,817
Common Class A [Member]
Other income (expense), net
Net loss attributable to Rani Therapeutics Holdings, Inc.	$ (33,970)	$ (30,588)
Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc.-basic	$ (1.33)	$ (1.28)
Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc.-diluted	$ (1.33)	$ (1.28)
Weighted average Class A common share outstanding-basic	25,505	23,817
Weighted average Class A common share outstanding-diluted	25,505	23,817

RANI Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 5,864	$ 27,007
Marketable securities	42,675	71,475
Prepaid expenses and other current assets	2,308	2,442
Total current assets	50,847	100,924
Property and equipment, net	6,105	6,038
Operating lease right-of-use asset	718	1,065
Other assets	246	0
Total assets	57,916	108,027
Current liabilities:
Accounts payable	648	1,460
Accrued expenses and other current liabilities	1,726	2,349
Current portion of long-term debt	4,897	0
Current portion of operating lease liability	718	1,006
Total current liabilities	7,989	4,815
Long-term debt, less current portion	24,484	29,149
Operating lease liability, less current portion	0	59
Total liabilities	32,473	34,023
Stockholders' equity:
Preferred stock, $0.0001 par value - 20,000 shares authorized; none issued and outstanding as of December 31, 2023 and December 31, 2022	0	0
Additional paid-in capital	85,762	75,842
Accumulated other comprehensive loss	(12)	(73)
Accumulated deficit	(72,889)	(38,919)
Total stockholders' equity attributable to Rani Therapeutics Holdings, Inc.	12,866	36,855
Non-controlling interest	12,577	37,149
Total stockholders' equity	25,443	74,004
Total liabilities and stockholders' equity	57,916	108,027
Common Class A [Member]
Stockholders' equity:
Common stock, value	3	3
Common Class B [Member]
Stockholders' equity:
Common stock, value	2	2
Common Class C
Stockholders' equity:
Common stock, value	$ 0	$ 0

About Rani Therapeutics Holdings, Inc.

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including large molecules, such as peptides, proteins, and antibodies. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company was incorporated in 2012 and is headquartered in San Jose, California.

CEO	Mr. Talat Imran
WEBSITE	ranitherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	163

Rani Therapeutics Holdings, Inc. Frequently Asked Questions

What is the ticker symbol for Rani Therapeutics Holdings, Inc.? What does RANI stand for in stocks?

RANI is the stock ticker symbol of Rani Therapeutics Holdings, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Rani Therapeutics Holdings, Inc. (RANI)?

As of Wed Apr 24 2024, market cap of Rani Therapeutics Holdings, Inc. is 174.36 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RANI stock?

You can check RANI's fair value in chart for subscribers.

What is the fair value of RANI stock?

You can check RANI's fair value in chart for subscribers. The fair value of Rani Therapeutics Holdings, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Rani Therapeutics Holdings, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RANI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Rani Therapeutics Holdings, Inc. a good stock to buy?

The fair value guage provides a quick view whether RANI is over valued or under valued. Whether Rani Therapeutics Holdings, Inc. is cheap or expensive depends on the assumptions which impact Rani Therapeutics Holdings, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RANI.

What is Rani Therapeutics Holdings, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, RANI's PE ratio (Price to Earnings) is -4.07 and Price to Sales (PS) ratio is 52.82. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RANI PE ratio will change depending on the future growth rate expectations of investors.